The research proposed by The University of Texas SPORE in Lung Cancer encompasses a broad range of lung cancer translational research activities, including studies in cell lines, xenografts and transgenic animal models, clinically and molecularly annotated tumor and other biospecimens, germline polymorphisms, and clinical trials. These studies will generate many different types of data, including clinical, epidemiological, biochemical, immunohistochemical, dose response, gene expression microarrays, sequencing, and more. The Core provides comprehensive expertise to ensure the statistical integrity, data integrity, data sharing, and data analysis of the studies performed by the SPORE, which are conducted at the University of Texas Southwestern Medical Center (UTSW), the M.D. Anderson Cancer Center (MDACC) and Ohio State University (OSU). The Core has a director at each institution (Xie at UTSW, Baladandayuthapani at MDACC, and Coombes at OSU) and has the flexibility to match personnel to the evolving needs of existing and developmental SPORE Projects. Members of the Core participate in monthly SPORE vide conferences linking researchers at UTSW in Dallas, TX, MDACC in Houston, TX and OSU in Columbus, Ohio, ensuring that proper consideration is taken of biostatistics and data management issues during all phases of SPORE experiments. The Core will develop and maintain systems for data storage, retrieval, analysis, and sharing. It will provide an interface for all SPORE investigators. The Core services are made possible by the accumulated experience, accumulated computer codes and resources, and by innovative, unique, sometimes customized approaches to solving the data analysis and interpretation challenges in the modern data centric research laboratory. To carry out its responsibilities, the Core has the following Specific Aims:
Aim 1 : To provide valid statistical designs of laboratory research, clinical trials and translational experiments arising from the ongoing research of the SPORE.
Aim 2 : To oversee and conduct the innovative statistical modeling, simulations, data analyses and data integration needed by the Projects, Developmental and Career Projects, and the other Cores to achieve their specific aims. A im 3: To ensure that the results of all Projects are based on well-designed experiments, appropriately interpreted, and to assist in the preparation of manuscripts describing these results. A im 4: To provide an integrated site for data storage and distribution for the SPORE Projects, particularly those with genome-wide and other data-dense Projects.

Public Health Relevance

The Biostatistics and Bioinformatics Core ensures that all experiments performed by the core are properly designed, and that the data collected by those experiments are stored safely, analyzed sensibly, and made available to other SPORE investigators (and ultimately to other lung cancer researchers) in order to further the ultimate goal of translating knowledge from the research lab into the clinic.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA070907-16A1
Application #
8747071
Study Section
Special Emphasis Panel (ZCA1-RPRB-C (M1))
Project Start
1996-09-30
Project End
2019-08-31
Budget Start
2014-09-23
Budget End
2015-08-31
Support Year
16
Fiscal Year
2014
Total Cost
$278,105
Indirect Cost
$55,727
Name
University of Texas Sw Medical Center Dallas
Department
Type
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Mender, Ilgen; LaRanger, Ryan; Luitel, Krishna et al. (2018) Telomerase-Mediated Strategy for Overcoming Non-Small Cell Lung Cancer Targeted Therapy and Chemotherapy Resistance. Neoplasia 20:826-837
Gong, Ke; Guo, Gao; Gerber, David E et al. (2018) TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer. J Clin Invest 128:2500-2518
Wang, Jacqueline F; Pu, Xingxiang; Zhang, Xiaoshan et al. (2018) Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing. Cancer 124:1061-1069
Rashdan, Sawsan; Minna, John D; Gerber, David E (2018) Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy. Lancet Respir Med 6:472-478
Pierzynski, Jeanne A; Ye, Yuanqing; Lippman, Scott M et al. (2018) Socio-demographic, Clinical, and Genetic Determinants of Quality of Life in Lung Cancer Patients. Sci Rep 8:10640
Akbay, Esra A; Kim, James (2018) Autochthonous murine models for the study of smoker and never-smoker associated lung cancers. Transl Lung Cancer Res 7:464-486
Zhang, Wei; Girard, Luc; Zhang, Yu-An et al. (2018) Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes. Transl Lung Cancer Res 7:32-49
Tan, Xiaochao; Banerjee, Priyam; Liu, Xin et al. (2018) The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network. J Clin Invest 128:1267-1282
McMillan, Elizabeth A; Ryu, Myung-Jeom; Diep, Caroline H et al. (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell 173:864-878.e29
Walser, Tonya C; Jing, Zhe; Tran, Linh M et al. (2018) Silencing the Snail-Dependent RNA Splice Regulator ESRP1 Drives Malignant Transformation of Human Pulmonary Epithelial Cells. Cancer Res 78:1986-1999

Showing the most recent 10 out of 1059 publications